**Sir**,

We read with interest the phase II results presented by [Kollmannsberger *et al* (2002b)](#bib5){ref-type="other"}, which recorded no responses to single-agent irinotecan delivered in a dose of 300--350 mg/m^−2^ every 3 weeks. This led the authors to conclude that further evaluation of irinotecan in patients with germ cell cancer could not be recommended. We note that other recent single-agent phase II studies in germ cell tumours (oxaliplatin, paclitaxel and gemcitabine ([Sandler *et al*, 1998](#bib7){ref-type="other"}; [Bokemeyer *et al*, 1999](#bib2){ref-type="other"}; [Kollmannsberger *et al*, 2002a](#bib4){ref-type="other"})) revealed very low objective response rates ([Table 1](#tbl1){ref-type="table"}Table 1Chemotherapy for relapsed/refractory germ cell tumours**Reference*****n*****TreatmentPrior exposure to platinum (cycles)Prior high-dose CT (%)Refractory/absolute refractory disease (%)Response rate PR/CR (%)Overall survival (months)**Kollmannsberger *et al*32Oxaliplatin77885135Sandler *et al*18Paclitaxel\>616NA113.5Bokemeyer *et al*31Gemcitabine77154196Hinton *et al*28Gemcitabine\>63636218  Paclitaxel     Bockemeyer *et al*15Irinotecan6867403IPO9Irinotecan7222255\>11  Paclitaxel       Oxaliplatin     [^1]) The patients treated in the studies are invariably heterogenous; however, most have proved refractory to at least two lines of cisplatin-based therapy and many have received prior high-dose therapy. Since the number of durable responses following high-dose therapy is of the region of only 4% and that 86% of patients in Kollmannsberger\'s manuscript had received high-dose therapy, we feel that the results are not particularly surprising. The median survival in all these studies is remarkably similar and in the region of 3--6 months. However, when gemcitabine and paclitaxel were given in combination, the overall survival was improved ([Hinton *et al*, 2002](#bib3){ref-type="other"}).

We have recently reported in this journal that there is an increased level of topoisomerase-1 expression in viable tumour samples from residual masses postchemotherapy ([Berney *et al*, 2002](#bib1){ref-type="other"}). Moreover, *in vitro* studies suggest that the active metabolite of irinotecan (SN38) may be active in germ cell tumours. Evidence for this comes from both published data ([Ueno *et al*, 2002](#bib9){ref-type="other"}) and currently unpublished work in progress, from our institution. SN38 appears to have impressive efficacy in both sensitive and platinum-resistant testicular cancer cell lines (sensitive testicular lines: IC~50~=1.8--7.4 nm, resistant testicular line: IC~50~=7.0 nm). It is for this reason that we have felt that the investigation of combination chemotherapy based on irinotecan was warranted. We have been evaluating a combination chemotherapy regimen using oxaliplatin 100 mg/ m^−2^ on 1 one, irinotecan 200 mg/ m^−2^ on day 1 and paclitaxel 80 mg/ m^−2^ on days 1, 8 and 15 (IPO), the treatment being repeated every 21 days. To date we have treated nine patients. Two had absolutely refractory disease to cisplatin and two had relapsed following high-dose chemotherapy. Four patients have had complete remissions and two have marker negative partial remissions. Currently, the median survival for this cohort has not been reached, with a median follow-up of 11 months (range 4--14). Both patients with absolute refractory disease are currently progression free 11 and 12 months after treatment.

We conclude that combining drugs with relatively low single-agent activity, leads to improved results in these patients. This effect has also been shown when oxaliplatin and irinotecan were combined in fluorouracil-resistant colorectal carcinoma, as compared to their single-agent activity ([Scheithauer *et al*, 1999](#bib8){ref-type="other"}). Our results are certainly comparable with those of Nomoto *et al*, who also used irinotecan in combination with cisplatin in relapsed disease; however, details regarding platinum sensitivity of their patients were not given (Nomoto *et al*, 2002). These *in vitro* and *in vivo* observations lead us to question whether single-agent phase II studies, conducted in a highly refractory patient population may best be able to identify potentially useful cytotoxics, and certainly a negative result must be accepted with some degree of caution.

[^1]: CT=chemothotherapy; PR=partail remission; CR=complete remission.
